Boundless Bio Inc.

BOLD | NASDAQ

Price Alert Chart Builder DCF Calculator

$2.87

+$0.04 (+1.41%)

Sep 22, 2026, 11:46 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.41%

(1D)

Rating

Updated: Aug 28, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $64.44M

1D Range

2.83 2.88

52W Range

0.96 3.16

Valuation (TTM)

PE -0.99

PB 0.96

EV/EBITDA 0.14

Valuation (NTM)

Forward PE N/A

Forward PEG 0.02

Price Target N/A

Cash Flow

FCF Yield -89.2%

SBC Adj. FCF Yield -100.6%

SBC Impact -12.7%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y -4.6% | 30.4%

FCF 3Y | 5Y 1.0% | 26.1%

Returns

ROA -86.8%

ROE -70.9%

ROIC -103.1%

Financial Health

Net Cash

$72.63M

Current Ratio 9.48

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Th...

Sector Healthcare

Industry Biotechnology

Employees 28

IPO Date Mar 27, 2024

Website boundlessbio.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.